GLP-1/GIP receptor (dual)
Assets acting on this target.
- Class
- Dual GLP-1/GIP receptor agonist
The GLP-1 and GIP receptors are class B G-protein-coupled receptors expressed on pancreatic beta cells, in the central nervous system, and in peripheral tissues including adipose tissue. Both are activated physiologically by incretin hormones released from the gut after eating, and both potentiate insulin secretion in a glucose-dependent manner, meaning insulin release is amplified only when blood glucose is elevated, which limits the risk of dangerously low blood sugar. GLP-1 receptor activation additionally suppresses glucagon secretion, slows gastric emptying, and promotes satiety signals in the brain, contributing to reduced food intake. GIP receptor activation contributes to lipid handling in fat tissue and may add metabolic benefits distinct from those of GLP-1 alone. A dual agonist engages both receptors simultaneously, aiming to combine the glucose-lowering and appetite-suppressing effects of GLP-1 signaling with the additional metabolic contributions of GIP signaling, with the goal of achieving greater improvements in blood sugar control and body weight than agonism at either receptor alone. This mechanism is broadly relevant to type 2 diabetes, where glycemic control is the primary aim, and to obesity, where appetite and energy balance are the therapeutic targets.
Related mechanisms
GLP-1/GIP receptor (dual) drugs compared
13 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Tirzepatide (Mounjaro)Mounjaro | Eli Lilly, Tanabe Pharma Corporation | peptide | Approved | Approved in Atherosclerotic Cardiovascular Disease; Approved in Type 2 Diabetes |
| Tirzepatide (Zepbound)Zepbound | Eli Lilly | peptide | Approved | Approved in Obesity; Phase 3 in Crohn's Disease; Phase 3 in Psoriasis; Phase 3 in Psoriatic Arthritis |
| BGM0504 | BrightGene Bio-Medical Technology, China Resources Sanjiu Medical & Pharmaceutical | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| Brenipatide | Eli Lilly | peptide | Phase 3 | Phase 3 in Alcohol Use Disorder; Phase 3 in Major Depressive Disorder; Phase 2 in Asthma; Phase 2 in Bipolar Disorder; Phase 2 in Chronic Obstructive Pulmonary Disease; Phase 2 in Opioid Use Disorder; Phase 2 in Schizophrenia; Phase 1 in Obesity |
| enicepatide | Chugai Pharma, Roche | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| HDM1005 | Hangzhou Zhongmei Huadong Pharmaceutical | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| olatorepatide | Hansoh Pharmaceutical Group, Regeneron Pharmaceuticals | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes; Phase 2 in Hidradenitis Suppurativa |
| RAY1225 | Guangdong Raynovent Biotech, Qilu Pharmaceutical | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| ribupatide | Jiangsu Hengrui Pharmaceuticals, Kailera Therapeutics | peptide | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 3 in Obesity; Phase 3 in Type 2 Diabetes; Phase 2 in Heart Failure |
| VK2735 | Viking Therapeutics | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| NNC0519-0130 | Novo Nordisk | peptide | Phase 2 | Phase 2 in Chronic Kidney Disease; Phase 2 in Obesity; Phase 2 in Type 2 Diabetes |
| THDBH120 | Tonghua Dongbao Pharmaceutical | peptide | Phase 2 | Phase 2 in Obesity |
| KP405 | Kariya Pharmaceuticals | peptide | Phase 1 | Phase 1 in Parkinson's Disease |